On Monday, Inovio Pharmaceuticals Inc (NASDAQ:INO)’s shares declined -7.04% to $6.54.
Inovio Pharmaceuticals (INO) recently declared its DNA vaccine targeting the virulent Middle East Respiratory Syndrome (MERS) induced 100% protection from a live virus challenge in a preclinical study. This medical advancement is notable because there is no vaccine or effective treatment for the MERS virus, which is clearly able to transmit from human to human. Since 2012, MERS has infected 1,400 people and killed over 500. Recently, the largest outbreak outside of Saudi Arabia of this emergent global health concern infected 186 people with 36 fatalities in South Korea.
In preclinical studies, Inovio and its collaborators evaluated its synthetic DNA-based MERS vaccine in mice, camels and monkeys, or non-human primates. In all three species, the vaccine induced robust immune responses capable of preventing the virus from infecting cells. The data from camels is an important finding because camels represent not only a host reservoir of the disease but act as a mode of transmission to humans. In monkeys, all vaccinated animals in the study were protected from symptoms of MERS disease when challenged with a live MERS virus. Inovio has stated on the preventive power of its synthetic DNA-based vaccines in a variety of infectious diseases counting HIV, influenza, hepatitis B, Ebola and dengue.
Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. The company’s SynCon immunotherapy design has the ability to break the immune system’s tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, in addition to new unmatched strains of pathogens, such as influenza.
Peregrine Pharmaceuticals (NASDAQ:PPHM)’s shares dropped -0.88% to $1.13.
Peregrine Pharmaceuticals, Inc. (PPHM) a biopharmaceutical company focused on developing novel investigational products that assist harness the body’s own immune system to fight cancer, declared financial results for the fourth quarter and the fiscal year (FY) 2015 ended April 30, 2015 and offered an update on its advancing clinical pipeline and other corporate developments.
Highlights Since January 31, 2015:
“During the fourth quarter, Peregrine achieved multiple milestones spanning all areas of the business. Most importantly, we remain on plan to complete patient enrollment in the SUNRISE Phase III trial in NSCLC by the end of calendar year 2015, while also planning for the initiation of two new trials designed to further expand our breast and non-small cell lung cancer clinical programs,” said Steven W. King, president and chief executive officer of Peregrine. “Our promising new partnership with Memorial Sloan Kettering Cancer Center, together with the considerable amount of pre-clinical and clinical data that has been generated, serves to further validate bavituximab and its potential to enhance the effects of chemotherapy, in addition to immune checkpoint targeting treatments. Recently, we are more confident than ever in bavituximab and we are plannedally expanding our clinical programs to capture the value that we believe exists in new therapeutic combinations and indications. Specifically, we are expanding our NSCLC clinical program to comprise a planned Phase II study combining bavituximab with Opdivo®, an FDA-approved PD-1 inhibitor, while also initiating a planned Phase II/III clinical trial in breast cancer combining bavituximab with chemotherapy. In addition to our drug development efforts, Avid achieved record revenue during this fiscal year 2015 and is on track to grow its revenue in FY 2016 based on the growing backlog of services and the near-term launch of the new manufacturing facility. We look forward to providing updates on our bavituximab clinical program, data from presently enrolling clinical trials and collaborative development efforts in the coming months.”
Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the research and development of novel monoclonal antibodies for the treatment and diagnosis of cancer in the United States. Its lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of second-line non-small cell lung cancer together with various investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. At the end of Monday’s trade, Pinnacle West Capital Corporation (NYSE:PNW)‘s shares dipped -2.48% to $61.70.
Pinnacle West Capital Corporation (PNW) Board of Directors declared a quarterly dividend of $0.595 per share of common stock, payable on September 1, 2015, to shareholders of record on August 3, 2015.
Pinnacle West Capital Corporation, through its partner, Arizona Public Service Company, provides retail and wholesale electric services primarily in the State of Arizona. It generates, transmits, and distributes electricity using coal, nuclear, gas, oil, and solar resources. The company serves about 1.2 million customers. It owns or leases about 6,426 megawatts of regulated generation capacity. The company was founded in 1920 and is headquartered in Phoenix, Arizona.
Tidewater Inc. (NYSE:TDW), ended its Monday’s trading session with -3.45% loss, and closed at $14.93.
Tidewater Inc. (TDW) declared that its Board of Directors declared on July 30, 2015, a quarterly cash dividend of $0.25 per share of common stock payable September 15, 2015, to shareholders of record on September 4, 2015.
Tidewater Inc. provides offshore service vessels and marine support services through the operation of a fleet of marine service vessels to the offshore energy industry worldwide. The company operates in Americas, Asia/Pacific, Middle East/North Africa, and Sub-Saharan Africa/Europe segments. It provides services in support of offshore exploration, field development, and production, counting towing of and anchor handling for mobile offshore drilling units; transporting supplies and personnel necessary to sustain drilling, workover, and production activities; offshore construction, remotely operated vehicle (ROV) operations, and seismic and subsea support; and various specialized services, such as pipe and cable laying.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
